Personalis (NASDAQ:PSNL) Trading 8.9% Higher - Still a Buy?

Key Points

• Personalis, Inc. saw its share price increase by 8.9% on Friday, reaching a last traded price of $7.37, despite a decrease in trading volume.
• Analysts have mixed views on PSNL, with Wall Street Zen upgrading it to a "hold," while HC Wainwright maintains a "buy" rating with a target price of $8.50.
• The company reported quarterly earnings of ($0.23) EPS, slightly beating expectations, but noted a revenue of $17.20 million, below the estimated $20.12 million.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report)'s share price shot up 8.9% on Friday . The company traded as high as $7.39 and last traded at $7.37. 699,572 shares changed hands during trading, a decline of 32% from the average session volume of 1,033,696 shares. The stock had previously closed at $6.77.

Analysts Set New Price Targets

Several analysts have recently commented on PSNL shares. Wall Street Zen raised shares of Personalis from a "sell" rating to a "hold" rating in a research report on Saturday, September 20th. HC Wainwright reissued a "buy" rating and set a $8.50 target price on shares of Personalis in a research report on Monday, September 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Personalis in a report on Saturday, September 27th. Finally, BTIG Research set a $6.00 target price on shares of Personalis in a research note on Wednesday, August 6th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.42.

Personalis Price Performance

The company has a market capitalization of $650.91 million, a price-to-earnings ratio of -5.73 and a beta of 1.83. The firm has a fifty day simple moving average of $5.40 and a 200 day simple moving average of $5.10.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%.The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts predict that Personalis, Inc. will post -1.4 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. American Century Companies Inc. raised its position in Personalis by 33.9% in the first quarter. American Century Companies Inc. now owns 67,377 shares of the company's stock worth $236,000 after acquiring an additional 17,056 shares in the last quarter. Trexquant Investment LP raised its position in Personalis by 455.0% in the first quarter. Trexquant Investment LP now owns 122,959 shares of the company's stock worth $432,000 after acquiring an additional 100,804 shares in the last quarter. Two Sigma Advisers LP raised its position in Personalis by 25.6% in the fourth quarter. Two Sigma Advisers LP now owns 34,300 shares of the company's stock worth $198,000 after acquiring an additional 7,000 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company's stock worth $998,000 after acquiring an additional 101,706 shares in the last quarter. Finally, XTX Topco Ltd raised its position in Personalis by 147.0% in the first quarter. XTX Topco Ltd now owns 82,666 shares of the company's stock worth $290,000 after acquiring an additional 49,197 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company's stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.